Literature DB >> 14734747

Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription.

David M Center1, William W Cruikshank, Yujun Zhang.   

Abstract

The precursor for IL-16 (pro-IL-16) is a nuclear and cytoplasmic PDZ domain-containing protein. In this study we have found that pro-IL-16 is absent or mutated in four T lymphoblastic leukemia cell lines examined. Ectopic expression of pro-IL-16 in pro-IL-16-negative Jurkat cells blocks cell cycle progression from G(0)/G(1) to S phase associated with elevated levels of the cyclin-dependent kinase inhibitor p27(KIP1). Pro-IL-16 decreases p27(KIP1) degradation by reducing transcription and subsequent expression of Skp2, a key component of the SCF(Skp2) ubiquitin E3 ligase complex. Taken together, these findings identify pro-IL-16 as a novel regulator of Skp2 expression and p27(KIP1) levels and implicate a role for pro-IL-16 in T cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734747     DOI: 10.4049/jimmunol.172.3.1654

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Interleukin-16 as a marker of Sézary syndrome onset and stage.

Authors:  Jillian Richmond; Marina Tuzova; Ashley Parks; Natalie Adams; Elizabeth Martin; Marianne Tawa; Lynne Morrison; Keri Chaney; Thomas S Kupper; Clara Curiel-Lewandrowski; William Cruikshank
Journal:  J Clin Immunol       Date:  2010-09-28       Impact factor: 8.317

2.  Introduction of pro-interleukin-16 inhibits T-lymphoblastic leukemia growth in mice.

Authors:  Jillian Richmond; Michael Finkel; Anna Studwell; Frederic Little; William Cruikshank
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-05       Impact factor: 4.553

3.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

4.  Adenovirus expressing p27kip1 suppresses growth of established esophageal carcinoma xenografts.

Authors:  Wei-Guo Zhang; Qing-Ming Wu; Jie-Ping Yu; Qiang Tong; Guo-Jian Xie; Xiao-Hu Wang; Sheng-Bao Li
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

5.  Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells.

Authors:  Wei-Guo Zhang; Jie-Ping Yu; Qing-Ming Wu; Qiang Tong; Sheng-Bao Li; Xiao-Hu Wang; Guo-Jian Xie
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 6.  Modulation of cell cycle regulators by HDACs.

Authors:  Elphine Telles; Edward Seto
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

7.  Cytokine Levels in Human Vitreous in Proliferative Diabetic Retinopathy.

Authors:  Dean F Loporchio; Emily K Tam; Jane Cho; Jaeyoon Chung; Gyungah R Jun; Weiming Xia; Marissa G Fiorello; Nicole H Siegel; Steven Ness; Thor D Stein; Manju L Subramanian
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

8.  Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease.

Authors:  Dorota Purzycka-Bohdan; Aneta Szczerkowska-Dobosz; Monika Zablotna; Justyna Wierzbicka; Anna Piotrowska; Michal A Zmijewski; Boguslaw Nedoszytko; Roman Nowicki
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

Review 9.  Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy.

Authors:  N M Luheshi; N J Rothwell; D Brough
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

10.  Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.

Authors:  Julia Templin; Djordje Atanackovic; Daniel Hasche; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.